Genome-editing technology has broad potential for treating cancers
the ONA take:
Researchers from the Walter and Eliza Hall Institute, in Melbourne, Australia, have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.
Using the technology, called CRISPR, the researchers were able to kill human lymphoma cells by locating and deleting an essential gene for cancer cell survival.
The technology can directly target any gene in a person’s genome, thereby overcoming many problems commonly encountered in drug development.
The system works by efficiently locating and targeting a particular gene. It can introduce mutations that make the genome nonfunctional, or introduce changes that make mutated genes function normally again.
The researchers report that the technology has a wide range of potential in terms of drug development for treating genetic diseases such as cancer.
Researchers have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|